In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors.

Abstract

SOURCE CITATION:

Douros A, Lix LM, Fralick M, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. Ann Intern Med. 2020;173:417-25. 32716707.

• Authors: Aris Liakos, Apostolos Tsapas, Eleni Bekiari
• Journal: Annals of internal medicine (Ann Intern Med) Vol. 173 Issue 12 Pg. JC70 (12 15 2020) ISSN: 1539-3704 [Electronic] United States
• PMID: 33316195 (Publication Type: Journal Article, Comment)

Chemical References

• Dipeptidyl-Peptidase IV Inhibitors
• Hypoglycemic Agents
• Sodium-Glucose Transporter 2 Inhibitors
• Sodium
• Glucose

Topics

• Cohort Studies
• Diabetes Mellitus, Type 2 (drug therapy)
• Diabetic Ketoacidosis (chemically induced)
• Dipeptidyl-Peptidase IV Inhibitors (adverse effects)
• Glucose
• Humans
• Hypoglycemic Agents (adverse effects)
• Sodium
• Sodium-Glucose Transporter 2 Inhibitors (adverse effects)